Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply
Abstract
No abstract available
Fichier principal
2023_Buisson_Aliment-Pharmacol_Therapeutics.pdf (176.19 Ko)
Télécharger le fichier
Origin | Publisher files allowed on an open archive |
---|---|
Licence |